Anthropic’s Long-Term Benefit Trust Adds Novartis CEO to Its Board

Anthropic has added a heavy hitter to its board. Vas Narasimhan, CEO of Novartis and a physician-scientist, has been appointed by the Anthropic Long-Term Benefit Trust. This isn’t just another corporate board shuffle. It’s a deliberate move that tells you something about where Anthropic thinks the real value of AI lies.

Narasimhan isn’t your typical tech board member. He’s overseen the development and approval of more than 35 novel medicines, working in what might be the most heavily regulated industry on the planet. Daniela Amodei, Anthropic’s co-founder and president, put it better than I could: “Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic. Vas has been doing exactly that for years.” That’s not flattery. It’s a statement of alignment.

What makes this appointment more significant is the governance angle. The Long-Term Benefit Trust is that rare thing in Silicon Valley: a body with no financial stake in the company. Its sole job is to keep Anthropic honest about balancing profit with its public benefit mission. With Narasimhan on board, Trust-appointed directors now hold a majority on the Board. That’s a meaningful structural shift, not just a PR talking point.

Narasimhan brings a perspective shaped by early work on HIV/AIDS, malaria, and tuberculosis programs in India, Africa, and South America. He’s an elected member of the US National Academy of Medicine and sits on the Council on Foreign Relations. This isn’t someone who’s spent his career in a lab or a boardroom. He’s seen how technology plays out in the real world, for better or worse.

The healthcare angle is the obvious hook here. AI in drug discovery and disease biology is already moving fast, and having someone who’s actually brought medicines to market could be genuinely useful. But I think the bigger story is the governance precedent. Most AI companies talk about long-term responsibility. Anthropic is actually building a board structure that makes it harder to abandon that mission when the pressure to monetize mounts.

Narasimhan joins a board that already includes Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell. It’s a diverse group in terms of background, but they’ve all shown they can navigate high-stakes environments. Adding someone who’s spent decades in one of the most regulated industries on earth feels like a bet on sustainability over speed.

I’m curious to see how this plays out. The trust-appointed majority is a bold move, but it only works if the trust itself stays independent and focused. For now, though, it’s one of the more interesting governance experiments in AI, and Narasimhan’s appointment feels like a serious step in the right direction.